Response to Finsterer and colleagues on ‘Prospective studies on the efficacy of rituximab for myasthenia gravis are warranted’

Saved in:
Bibliographic Details
Published inEuropean journal of neurology Vol. 27; no. 12; p. e94
Main Authors Dos Santos, A., Pereon, Y., Wiertlewski, S., Magot, A.
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.12.2020
Subjects
Humans
Immunotherapy
Monoclonal antibodies
Myasthenia
Myasthenia gravis
Myasthenia Gravis - drug therapy
neurological disorders
neuromuscular diseases
Neuromuscular junctions
Prospective Studies
Receptors, Cholinergic
Rituximab
Rituximab - therapeutic use
neuromuscular diseases
myasthenia
rituximab
neurological disorders
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:1351-5101
1468-1331
DOI:10.1111/ene.14460